

Appendix 1. Seasonal Influenza Vaccine PGDs 2018-2019

National Contract Influenza Vaccines						
Manufacturer/Supplier	Name of product	Vaccine Type	Age Indication	Ovalbumin content per 0.5ml dose	Latex Formaldehyde Other	Amino-glycosides
Astra Zeneca UK Ltd	Fluenz Tetra®	Quadrivalent live attenuated	From 24 months to less than 18 years of age	≤0.024 µg (0.2ml dose)	Latex free Gelatin (porcine) Formaldehyde free	Gentamicin
Sanofi Pasteur MSD	Quadrivalent Influenza vaccine (split virion)	Quadrivalent Split virion inactivated	From 6 months	≤0.05 µg	Latex free Risk of formaldehyde residue	Neomycin
Pfizer	Influenza Vaccine ^{1,2}	Trivalent Split virion inactivated	From 9 years	≤1 µg	Latex free Formaldehyde free	Neomycin Polymixin
	Enzira®					
Sequirus	Fluad®▼	Trivalent Surface Antigen, Inactivated Adjuvanted with MF59C.1	From 75years	≤0.2 µg	Latex free Risk of formaldehyde residue	Kanamycin Neomycin
Mylan	Tetra Myl®▼	Quadrivalent Surface antigen	From 18 years	≤0.1 µg	Latex free Risk of Formaldehyde residue	Gentamicin
	Influvac®	Trivalent Surface antigen inactivated	From 6 months	≤0.1 µg	Latex free Risk of formaldehyde residue	Gentamicin
	Influenza Vaccine	Trivalent Surface antigen inactivated	From 6 months	≤0.1 µg	Latex free Risk of formaldehyde residue	Gentamicin

Other vaccines may be available on the UK market, only National Contract vaccines are listed in this appendix.

None of the influenza vaccines for the 2018/19 season contain thiomersal as an added preservative.

¹Age indications and exclusions for use of Pfizer (Seqirus) Influenza vaccine are based on Green book recommendations rather than licensed indication.

²The manufacturer states "Although no natural rubber latex is detected in the syringe tip cap, the safe use of this vaccine in latex-sensitive individuals has not been established".

Aminoglycoside content values not available for all vaccines, all those stated would be present as trace compounds as they are used in the early stages of vaccine production. N.b. cross sensitivity to aminoglycosides is common, assume potential reaction for all, if allergic response to one has been demonstrated.

There is no egg free influenza vaccine marketed in the UK for the 2018-19 season

Ovalbumin, latex and aminoglycoside content for vaccines are correct as at August 2018, however, these may be subject to change in manufacturing practice at any time. Guidance on the management of egg allergy is available <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2222.2010.03557.x/full>